XML 188 R19.htm IDEA: XBRL DOCUMENT v3.20.1
ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Tables)
 3 Months Ended
Mar. 31, 2020
Accounting Policies [Abstract]  
Schedule of Revenue from Strategic Partnering Collaboration Agreements and Research Activity Grants as a Percentage of Total Revenues Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:
Three Months Ended March 31,
20202019
Kite Pharma, Inc.55 %75 %
Pfizer27 %N/A  
Sanofi4 %18 %
Schedule of Cash and Cash Equivalents
A reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):
March 31,
2020		December 31,
2019		March 31,
2019		December 31,
2018
 Cash and cash equivalents$85,749  $80,428  $80,968  $140,418  
 Non-current restricted cash1,500  1,500  3,500  3,500  
Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows$87,249  $81,928  $84,468  $143,918